Severe adverse events reported with IV iron relative to any comparator (placebo, no iron, oral iron, intramuscular iron)
| Severe adverse events . | RR (95%) . |
|---|---|
| All iron studies | 1.04 (0.93-1.17) |
| SAE by compound | |
| Ferric carboxymaltose | 0.82 (0.64-1.06) |
| Ferric gluconate | 1.12 (0.96-1.30) |
| Ferumoxytol | 1.04 (0.71-1.53) |
| Iron dextran | 1.05 (0.77-1.45) |
| Iron isomaltose/polymaltose | 1.09 (0.43-2.80) |
| Iron sucrose | 1.33 (0.96-1.83) |
| Infusion reactions | 2.47 (1.43-4.28)* |
| Mortality | 1.06 (0.81-1.39) |
| Infections | 1.17 (0.83-1.65) |
| Gastrointestinal | 0.55 (0.51-0.61)* |
| Severe adverse events . | RR (95%) . |
|---|---|
| All iron studies | 1.04 (0.93-1.17) |
| SAE by compound | |
| Ferric carboxymaltose | 0.82 (0.64-1.06) |
| Ferric gluconate | 1.12 (0.96-1.30) |
| Ferumoxytol | 1.04 (0.71-1.53) |
| Iron dextran | 1.05 (0.77-1.45) |
| Iron isomaltose/polymaltose | 1.09 (0.43-2.80) |
| Iron sucrose | 1.33 (0.96-1.83) |
| Infusion reactions | 2.47 (1.43-4.28)* |
| Mortality | 1.06 (0.81-1.39) |
| Infections | 1.17 (0.83-1.65) |
| Gastrointestinal | 0.55 (0.51-0.61)* |
No fatal reactions or anaphylaxis reported in 103 trials composing 10 390 treated with IV iron. Adapted from Avni et al26 with permission.
Significant.